Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hudson Bay Capital Buys More $CPRX

Hudson Bay Capital revealed 1,025,824 shares in Catalyst Pharmaceutical Partners, Inc. (CPRX) on October 31st, corresponding to a 4.15% passive stake. The firm reported 683,429 shares in CPRX in its last 13F filing, so this is a 50% expansion in its position. Hudson Bay Capital might enter at about $1.35 when CPRX is wavering throughout October. According to the 13G release, Hudson Bay Capital once had more than 5% stake in CPRX on or near October 28th. Now CPRX is trading at $1.04 after its public offering of common shares and warrants on Friday.

From Bloomberg Businessweek, Hudson Bay Capital Management is “an employee owned hedge fund sponsor. The firm invests in the public equity and hedging markets across the globe. It employs multi-strategy approach to make its investments. It was formerly known as Gerber Capital Management. Hudson Bay Capital was founded in 1997 and is based in New York City”.

Catalyst Pharmaceutical Partners, Inc. is a development-stage biopharmaceutical company. It focuses on the development and commercialization of prescription drugs for the central nervous system. The company mainly develops CPP-109 and CPP-115. The company was founded in 2002 and is based in Coral Gables, Florida.

Loading...